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nhibitors and Angiotensin Receptor Blockers
Meta-Analysis
eff S. Healey, MD,* Adrian Baranchuk, MD,* Eugene Crystal, MD,† Carlos A. Morillo, MD,*
ichael Garfinkle, BA,† Salim Yusuf, MD, PHD,* Stuart J. Connolly, MD*
amilton and Toronto, Ontario, Canada
OBJECTIVES This study was designed to identify all randomized clinical trial data evaluating angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers for the prevention of atrial
fibrillation (AF), to estimate the magnitude of this effect and to identify patient subgroups
most likely to benefit.
BACKGROUND Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers
(ARBs) reduce morbidity and mortality in patients with heart failure, vascular disease, and
hypertension. Several reports suggest that they may also prevent the development of AF.
METHODS A systematic review of the literature was performed to identify all reports of the effect of
ACEIs or ARBs on the development of AF. Eligible studies had to be randomized,
controlled, parallel-design human trials of an ACEI or ARB that collected data on the
development of AF.
RESULTS A total of 11 studies, which included 56,308 patients, were identified: 4 in heart failure, 3 in
hypertension, 2 in patients following cardioversion for AF, and 2 in patients following
myocardial infarction. Overall, ACEIs and ARBs reduced the relative risk of AF by 28%
(95% confidence interval [CI] 15% to 40%, p  0.0002). Reduction in AF was similar
between the two classes of drugs (ACEI: 28%, p  0.01; ARB: 29%, p  0.00002) and was
greatest in patients with heart failure (relative risk reduction [RRR]  44%, p  0.007).
Overall, there was no significant reduction in AF in patients with hypertension (RRR 12%,
p 0.4), although one trial found a significant 29% reduction in patients with left ventricular
(LV) hypertrophy. In patients following cardioversion, there appears to be a large effect (48%
RRR), but the confidence limits are wide (95% CI 21% to 65%).
CONCLUSIONS Both ACEIs and ARBs appear to be effective in the prevention of AF. This benefit
appears to be limited to patients with systolic left ventricular dysfunction or LV
hypertrophy. The use of these drugs following cardioversion appears promising but
requires further study. (J Am Coll Cardiol 2005;45:1832–9) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.070College of Cardiology Foundation
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engiotensin-converting enzyme inhibitors (ACEIs) and
ngiotensin-II receptor blockers (ARBs) reduce morbidity
nd mortality in patients with heart failure (HF) (1,2) or
ystolic dysfunction after myocardial infarction (MI) (3–5)
nd are effective in the treatment of hypertension (6).
etrospective analyses of some of these trials suggest that
hese medications may prevent the development or recur-
ence of atrial fibrillation (AF) (7–14). Atrial fibrillation is
ssociated with a higher risk of stroke, death, and HF. It is
herefore important to understand the effect of these agents
n the occurrence of AF (15,16).
There are several potential mechanisms by which
nhibition of the renin-angiotensin-aldosterone system
RAAS) with ACEIs and ARBs may reduce AF. Al-
From the *Population Health Research Institute, McMaster University, and
amilton Health Sciences, Hamilton, Ontario, Canada; and †University of Toronto,
oronto, Ontario, Canada.s
Manuscript received October 8, 2004; revised manuscript received November 15,
004, accepted November 29, 2004.hough certain drugs may possess direct anti-arrhythmic
roperties (17), in animal models ACEIs and ARBs
ppear to prevent AF by attenuating changes in cardiac
tructure and function (18 –22). In these studies, these
rugs prevented left atrial dilation, atrial fibrosis, and
onduction velocity slowing, and these changes were
ssociated with a lower rate of AF induction with atrial
acing (18,22–24). One study demonstrated that these
enefits were not seen in animals treated to identical
emodynamic targets with hydralazine and isosorbide
ononitrate, suggesting that the beneficial effect is spe-
ifically related to RAAS inhibition (23).
There have been few prospectively designed clinical trials
o test whether ACEIs and ARBs prevent AF (7,12).
everal secondary analyses of large randomized trials suggest
benefit. A systematic review of published and unpublished
ata is timely and provides the best way to estimate of the
ffectiveness of ACEIs and ARBs and identify patient
ubgroups who may be most likely to benefit.
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comprehensive search was conducted to identify all
uman randomized controlled trials of ACEIs or ARBs that
ecorded new or recurrent AF as an outcome. Medline and
mbase were searched for any relevant human randomized
ontrolled trials or reviews published since 1980, using the
erms “angiotensin-converting enzyme inhibitor,” “angio-
ensin receptor blockers,” the individual names of all drugs
n these classes, and “atrial fibrillation.” The search was
imited to English-language publications. Two reviewers
hen independently evaluated identified titles, and manu-
cripts were retrieved for any publication that either re-
iewer felt was potentially relevant. Additional publications
ere sought using the reference lists of identified papers;
ublished reviews on the topic; and a manual search of
bstracts from the scientific sessions of the American
ollege of Cardiology, the American Heart Association, the
uropean Society of Cardiology, and the North American
ociety of Pacing and Electrophysiology during the past
our years. Finally, a second Medline search was done
ithout the term “atrial fibrillation” to identify additional
andomized controlled trials of ACEIs and ARBs that
ight contain data on AF. The results sections and tables of
hese studies were then examined to see if data on AF were
eported. Attempts were made to contact authors of ACEI
r ARB trials that did not report on AF.
Two blinded reviewers re-evaluated all of the abstracts
nd manuscripts identified as potentially relevant, and
ublications were selected for this review if both reviewers
elt that they met the following criteria: 1) randomized
ontrolled human trials with parallel design, 2) comparing
n ACEI or ARB to an alternative therapy, and 3) collect-
ng data on AF during follow-up. Studies were included in
his review if both authors felt they were relevant. Any
iscordance between reviewers was resolved by consensus.
Relevant study data were independently abstracted, in
uplicate, using a standardized form. Any discrepancies
uring data abstraction were resolved by consensus. For
tudies using a factorial design, data on all patients were
sed in this analysis. Data analysis was performed with
eview Manager 4.1 using the random-effects model. Effect
izes were weighted by the sample size to calculate a
eighted mean effect size using the Dersimonian and Laird
Abbreviations and Acronyms
AF  atrial fibrillation
ACEI  angiotensin-converting enzyme inhibitor
ARB  angiotensin-II receptor blocker
CI  confidence interval
HF  heart failure
LVEF  left ventricular ejection fraction
MI  myocardial infarction
RAAS  renin-angiotensin-aldosterone system
RRR  relative risk reductionethod (25), and the chi-square test was used to assess for reterogeneity between studies. The effect of treatment was
resented using the relative risk.
dentified studies. Our database search identified a total of
,021 randomized controlled human trials of ACEIs or
RBs, 85 of which included the term “atrial fibrillation.”
n additional 14 studies were identified from conference
roceedings. These 99 manuscripts and abstracts were
lindly reviewed by two investigators who identified 10
elevant studies: 6 from the literature search and 4 from the
eview of conference proceedings. There was 100% agree-
ent between the two reviewers in the identification of
tudies. Next, the titles of studies identified in the database
earch that did not contain the term “atrial fibrillation” were
eviewed, and 95 were searched for data on AF. This yielded
nother two relevant studies with data on AF (26,27).
uthors of ACEI and ARB trials that did not present data
n AF were contacted to determine if unpublished data
xisted. No additional available data were identified in this
ashion; however, at least two large trials of ACEIs had
ollected data on AF but have not yet analyzed or presented
he results: Antihypertensive and Lipid-Lowering Treat-
ent to Prevent Heart Attack Trial (ALLHAT) (28) and
eart Outcomes Prevention Evaluation (HOPE) study
29). In total, 12 relevant publications were identified,
ncluding two reports from the Studies Of Left Ventricular
ysfunction (SOLVD), one examining the incidence of AF
t a single large center (11) and the other describing hospital
dmissions for atrial tachyarrhythmias for the entire study
opulation (30). Despite a smaller number of outcome
vents (55 of 374 vs. 158 of 6,797), the single-center data
ere used for this analysis because its primary outcome, the
ccurrence of AF, was selected as the outcome event for this
eta-analysis. Hospitalization for AF, the primary outcome
f the other report (30), captured too many other variables
nd did not directly answer the primary question of this
eta-analysis. A sensitivity analysis using the data from this
lternative publication (30) was performed.
ESULTS
f the identified studies, eight were published in manuscript
orm and three as abstracts. The characteristics of included
tudies are summarized in Tables 1 and 2. Study populations
nd trial design were quite different. There were 56,308
atients in the identified studies: 26,403 in three hypertension
rials (13,26,27), 17,711 in a trial of patients following MI (14),
,577 in a second post-MI trial that enrolled only patients with
eft ventricular (LV) dysfunction (9), 10,319 in four trials of
F (8,11,28,31), and 299 in two post-AF cardioversion trials
7,12). Angiotensin-converting enzyme inhibitors were studied
n seven trials and ARBs in four (Table 1). The definition of
F (new vs. all) and the methods used to document AF were
ifferent between studies (Table 2) but were similar enough to
ermit pooled analysis.
Overall, the use of ACEIs or ARBs reduced the relativeisk of developing AF by 28% (95% confidence interval [CI]
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Prevention of AF With Angiotensin Inhibition June 7, 2005:1832–95% to 40%, p  0.0002). There were similar benefits seen
ith ACEIs (relative risk reduction [RRR]  28%, 95% CI
% to 44%, p  0.01) and ARBs (RRR  29%, 95% CI
6% to 40%, p  0.0002). However, there were significant
ifferences in treatment effect between individual trials, as
ndicated by the statistical test for heterogeneity (p 
.00001) (Fig. 1). Patients with the highest rate of AF
ppeared to benefit the most (Table 1); however, the variability
etween studies was not explained by this factor alone. Further
xploratory analyses determined that differences in study
opulations accounted for much of this heterogeneity and
hat the class of drug employed did not (Figs. 1 and 2). The
able 1. Characteristics of Included Studies
Author/Study, Date Patient Group Drug
CEI trials
Van den Burg, 1995 AF, CHF Lisinopril
Ueng, 2003 AF Enalapril
Vermes (SOLVD), 2003 LVD, CHF, NSR Enalapril
Pizetti (GISSI), 2001 Post-MI, NSR Lisinopril
Pedersen (TRACE), 1999 Post-MI, LVD, NSR Trandolapril
STOP-H2, 1999 HTN Enalapril
CAPP, 1999 HTN Captopril
RB trials
CHARM, 2003* CHF, NSR Candesartan
Madrid, 2002 AF Irbesartan
ValHeFT, 2003* CHF, NSR Valsartan
Wachtell, (LIFE), 2003* HTN, LVH, NSR Losartan
Abstract only.
ACEI  angiotensin-converting enzyme inhibitor; AF  atrial fibrillation; ARB
VD left ventricular dysfunction; LVEF left ventricular ejection fraction; LVH
able 2. Design of Included Studies
Author/Study, Date Placebo-Controlled Blinded De
an den Berg, 1995 Yes Yes Recurr
edersen (TRACE), 1999 Yes Yes New A
izetti (GISSI), 2001 Yes Yes In hos
pres
ECG
adrid, 2002 No No Recurr
ermes (SOLVD), 2003 Yes Yes New A
eng, 2003 No No Recurr
achtell (LIFE), 2003* ACTIVE control Yes New A
alHeFT, 2003* Yes Yes New A
HARM, 2003* Yes Yes New A
TOP-H2, 1999 ACTIVE control No All AF
APP, 1999 ACTIVE control No New AAbstract only.
AF  atrial fibrillation; ECG  electrocardiogram.ffect of ACE inhibitors and ARBs in different patient popu-
ations is displayed in Figure 2 and is summarized below.
ost-MI. Two studies examining the use of ACEIs fol-
owing MI came to different conclusions regarding their
tility in preventing AF. The Effects of Lisinopril and
ransdermal Glycerol Trinitrate Singly and Together on
-week Mortality and Ventricular Function after AMI
GISSI-3) found no significant reduction in AF with 6
eeks of ACEI therapy initiated within 24 h of MI (14),
hereas the Trandolapril Cardiac Evaluation (TRACE)
rial found a 48% relative risk reduction (95% CI 13% to
9%) in patients treated with trandolapril, starting 3 to 7
No.
omized Mean Follow-Up
Mean
LVEF % HTN
Rate of AF in
Control Group
30 84 days n/a n/a 64%
145 270 days (61–575) 51 32 43%
374 3.3 yrs 27 20 24%
,711 42 days n/a 30 8%
,577 2–4 yrs 33 22 5%
,985 5.0 yrs n/a 100 8%
,614 6.1 yrs n/a 100 2%
,518 3.2 yrs 39 55 8%
154 254 days (60–710) 64 42 29%
,409 2 yrs 28 7 8%
,193 4.9 yrs n/a 100 6%
giotensin receptor blocker; CHF  congestive heart failure; HTN  hypertension;
entricular hypertrophy; NSR sinus rhythm; Post-MI post-myocardial infarction.
n of AF How AF Diagnosed Outcome Assessment
F 24-h Holter at 6 and 12-weeks Blinded investigator
ECG at month 1, 2, and then
Q-3 months
Blinded local
investigator
F, not
admission
All in-hospital ECG Blinded local
investigator
F 24-h Holter at 1, 6, 12 months
Weekly ECG  4, then at
2, 3, 6, 12 months or if
symptoms
Blinded investigator
All available clinical ECG
No routine ECG
Blinded investigator
F 10 min Event recorder daily 90 s
24 h Holter at 1, 6, 12
months ECG weekly 4,
then monthly and with
symptoms
Investigator
Yearly ECG Blinded investigator
Recorded as study adverse
event
Blinded local
investigator
Assessed at last patient visit
and with symptoms
Local investigator
Yearly ECG and if symptoms Events committee
Not stated Most by committeeRand
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ncidence of AF was higher in GISSI-3 (Table 1), and,
iven its much larger size, the number of patients with AF
as more than 20 times that seen in the TRACE study. In
ddition to differences in follow-up periods, the TRACE
tudy enrolled only patients with LV dysfunction, whereas
n the GISSI-3 trial 84% of patients had no evidence of HF
t the time of MI (14) (Table 1).
eart failure. In four trials studying ACEIs or ARBs in
atients with HF (8,10,11,31), there was an overall 44%
elative risk reduction in the development of AF (p 0.007,
5% CI 15% to 63%). All trials demonstrated a significant
eduction in AF, although there was still considerable
eterogeneity between trials (p  0.002) (Fig. 2). Both
CEIs and ARBs reduced AF, despite the fact that many
atients in the ARB trials were already receiving ACEIs.
here appeared to be a relationship between the relative risk
eduction and LV ejection fraction. Patients in the SOLVD
ubstudy had the most severely impaired LV function (mean
eft ventricular ejection fraction [LVEF]  26.7%) and the
argest reduction in AF (RRR  78%). As mean LVEF in
F studies increased, the RRR with therapy decreased
Valsartan Heart Failure Trial [ValHeFT]: mean LVEF 
8%, RRR  23%; Candesartan in Heart Failure
CHARM]: mean LVEF  39%, RRR  18%). However,
he CHARM program, which enrolled patients with nor-
al and impaired LV function into distinct studies, found a
onsistent reduction in AF in both groups (31). No indi-
igure 1. Prevention of atrial fibrillation with angiotensin-converting en
onfidence interval; RR  relative risk.idual study reported on the relationship between ejection wraction and the reduction in AF seen with RAAS
nhibition.
ypertension. Three trials compared ACEIs (26,27) or
RBs (13) to other agents in the treatment of hypertension
Fig. 2). Overall, there was no significant reduction in AF
RR  0.88, 95% CI 0.66 to 1.19, p  0.4). However, the
esults from hypertension trials are statistically heteroge-
eous (chi-square test, p  0.001) despite similar follow-up
eriods (Table 1). Only the Losartan Intervention For
ndpoint reduction in hypertension (LIFE) trial demon-
trated a significant reduction in AF (13). The LIFE trial
as also the only one of the three studies to use an ARB,
nd it was the only one to enroll only patients with evidence
f LV hypertrophy (13). The CAPP and Swedish Trial in
ld Patients with Hypertension-2 (STOP-H-2) trials stud-
ed general hypertensive populations (26,27). In the Capto-
ril Prevention Project (CAPP) and STOP-H-2, there was
o reduction in AF with ACEIs compared to beta-blockers,
alcium channel antagonists, and diuretics (26,27).
econdary prevention of AF following cardioversion. Two
andomized trials were designed to test whether an ACEI
12) or an ARB (7) would reduce the recurrence of AF in
atients following electrical cardioversion (Fig. 2). Most
atients in these trials had hypertension with preserved LV
unction (Table 1). Both studies showed a significant re-
uction in AF with treatment (Fig. 2), which was apparent
ithin weeks of the cardioversion. Both studies were small,
ad a short follow-up period, and, although randomized,
inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). CI ere not placebo controlled (Table 2).
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Prevention of AF With Angiotensin Inhibition June 7, 2005:1832–9ffects of study size, methodology, publication bias, and
tudy selection. The five trials showing the largest effect of
reatment (7–9,11,12) were also the five smallest, and
ogether accounted for 5% of patients in this analysis.
his systematic review did not find any corresponding small
egative trials, and thus there is suggestion of publication
ias. Although publication bias could result in an overesti-
ation of treatment effect, this would not likely produce a
ualitative change in the results of this analysis, given the
elatively large number of patients in this analysis. Indeed, a
ensitivity analysis, which excluded all reports of 1,000
atients, still found a significant reduction in AF with
CEIs or ARBs, but the apparent treatment effect was
onsiderably smaller, with a relative risk reduction of 18%
95% CI 5% to 29%, p  0.01).
Overall, the duration of follow-up in individual trials did
ot appear to influence the effect of therapy (Table 1, Fig.
). However, the methods used to document AF may have
ad an impact. Most trials used only periodic electrocardio-
rams to document AF, usually no more than once per year
Table 2). However, the two post-cardioversion trials (7,12)
nd two of the HF trials (8,9) performed extensive investi-
ations to document AF (Table 2), and, in these four trials,
Figure 2. Prevention of atrial fibrillation in variohe benefit seen with ACEIs or ARBs was greater than all put one of the other trials in this analysis (Fig. 1). This may
imply suggest that the benefit of ACEIs and ARBs is more
pparent if one uses more sensitive techniques to document
F. Alternatively, these drugs may have a lesser effect on
he development of sustained AF that is more likely to be
ocumented on infrequent electrocardiograms.
There were two reports from the SOLVD study regard-
ng AF (11,30); the one used for this meta-analysis reported
pisodes of AF from a single site (11), the other reported
ospitalizations for atrial arrhythmias for the entire
OLVD study population (30). A sensitivity analysis was
one using data from the second publication, which found
hat hospitalizations for atrial arrhythmias occurred in 68 of
,401 patients randomized to enalapril and 90 of 3,396
andomized to placebo. The use of these data instead of the
ingle-center publication lowered the apparent effect from a
elative risk reduction of 29% to a relative risk reduction of
2% (95% CI 11% to 33%, p  0.0004).
ISCUSSION
his meta-analysis, based on 11 randomized controlled
rials, indicates that both ACEIs and ARBs are effective at
tient populations. Abbreviations as in Figure 1.reventing the development of AF. This effect appears to be
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nd clinical HF (9,11). In patients treated for hypertension,
reduction in AF was seen only in one trial evaluating
ubjects with established LV hypertrophy (13,26,27). Lim-
ted data suggests that ACEIs and ARBs reduce AF
ollowing cardioversion (7,12).
There are several possible biologic mechanisms by which
CEIs and ARBs might reduce the development of AF.
ne ARB agent has been reported to possess direct anti-
rrhythmic properties (17). However, the greater effective-
ess of these agents in patients with HF and LV dysfunc-
ion and a greater reduction in AF among patients with
ore severely impaired ejection fraction suggests that their
enefit may be related to an improvement in cardiac
emodynamics and a reduction in LV and left atrial wall
tress.
The hypertension trials (13,26,27) did not demonstrate a
onsistent reduction in AF with ACEIs and ARBs. The
verall apparent lack of AF prevention in the hypertension
rials may reflect the less severe hemodynamic abnormalities
n these patients, or, alternatively, result from the use of
lternative antihypertensive agents in the control groups of
hese trials. The hypertension trials were the only trials in
his systematic review to use an active therapy in their
ontrol groups; therefore, assuming that AF prevention is
he result of blood pressure lowering, it is possible that
ntihypertensive therapy in the control group may also have
revented AF, thereby obscuring any benefit of ACEIs.
ndeed, there is some evidence to suggest that other anti-
ypertensive agents, such as calcium channel blockers, may
lso prevent AF (32). These explanations are consistent with
he reduction in AF observed in the LIFE trial (13), the
nly hypertension trial to show a reduction in AF with
AAS inhibition. This study enrolled only patients with
V hypertrophy, a group of hypertensive patients with more
dvanced hemodynamic abnormalities. As well, the com-
arative treatment in the LIFE trial was beta-blockers, a
lass of agents that is less effective at reducing LV hyper-
rophy (33) and possibly less effective at preventing AF.
The ACEIs and ARBs likely prevent AF by reversing
hanges in cardiac structure and function. Left ventricular
ypertrophy and left atrial enlargement are elements of
ardiac remodeling that are frequent complications of hy-
ertension and HF and have a strong association with the
evelopment of clinical AF (34–36). Enlargement of the
eft atrium and increased atrial pressure may promote the
evelopment and maintenance of AF by triggering prema-
ure atrial beats (37), slowing atrial conduction velocity, and
roviding a greater area for re-entry (19–22,38). In animal
odels of HF, ACEIs and ARBs reduce aspects of cardiac
emodeling such as left atrial dilation, dysfunction, fibrosis,
nd shortening of the atrial effective refractory period
18,22–24); which should, in turn, lead to a reduction in AF
19–21). In one study, enalapril reduced atrial structural and
lectrical remodeling and AF to a greater extent than
ydralazine and isosorbide mononitrate (18), suggesting bhat ACEIs may also prevent remodeling and AF by
dditional mechanisms beyond improved hemodynamics.
tudy limitations. The majority of trials included in this
nalysis were post-hoc reports of randomized trials designed
o assess outcomes other than AF. Thus, these data may be
rone to multiple-testing error and data-derived emphasis
iases. As well, at least 4 additional large trials (HOPE [29],
LLHAT [28], European Trial on Reduction of Cardiac
vents with Perindopril in Stable Coronary Artery Disease
EUROPA] [39], and Valsartan Antihypertensive Long-
erm Use Evaluation [VALUE] [40]), with a collective
otal of approximately 70,000 patients, have not yet reported
ny results on AF, and could potentially affect the results of
his analysis. Assuming a 5% incidence of AF, which would
e similar to the rate of AF in the hypertension trials already
n this analysis, 3,500 events are likely to have occurred in
hese trials. However, even if the results of all of these trials
ere neutral (RR  1.0), a significant reduction in AF with
CEIs or ARBs would still be seen (RRR  18%, p 
.001, 95% CI 8% to 28%).
Trial methodology may also have had an impact on the
stimate of treatment effect. The two post-cardioversion
rials both showed a large treatment effect; however, neither
as placebo-controlled, only one trial clearly reported that
F was assessed in a blinded fashion (7), and only one trial
ollowed the intention-to-treat principle (7). All of these
esign issues could inflate the apparent effect of treatment.
ecommendations for clinical practice. It is premature to
ecommend an ACEI or ARB solely for the prevention or
reatment of AF, but these data raise the possibility of an
dded benefit in patients receiving either agent for HF or
ypertension. This benefit underscores the importance of
sing ACEIs and ARBs in patients with established
ndications.
eed for a definitive trial. Additional prospective research
s required to determine the impact of empiric use of ACEIs
r ARBs in patients with AF and to clarify the mechanisms
esponsible for any reduction in AF recurrence or cardio-
ascular events. The irbesartan arm of the Atrial Fibrillation
lopidogrel Trial with Irbesartan for Prevention of Vascular
vents (ACTIVE-I) trial will randomize 9,000 patients
ith a history of AF, with or without a history of hyper-
ension, to receive an ARB, irbesartan, or placebo. The
ean follow-up is three years, and the primary outcome is
he composite of stroke, MI, and vascular death. Substudies
f ACTIVE-I will examine the effects of irbesartan on the
ecurrence of paroxysmal AF and on the development of
tructural cardiac remodeling. As well, additional large trials
f ARBs (such as Ongoing Telmisartan Alone and in
ombination with Ramipril Global Endpoint Trial/
elmisartan Randomized Assessment in ACE Intolerant
ubjects with Cardiovascular Disease [ONTARGET/
RANSCEND]) are prospectively assessing the effects of
RBs on AF as a secondary outcome (41). Finally, a similar
nalysis examining the development of AF in trials of
eta-blockers or aldosterone antagonists in HF would be
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Prevention of AF With Angiotensin Inhibition June 7, 2005:1832–9seful to help determine if the reduction in AF is specific to
AAS inhibiting agents; however, such an analysis was not
easible as part of this study, as there are currently no
ublished manuscripts with data on AF incidence from
hese trials. Once available, these results will expand our
urrent understanding of the role of ACEI or ARB therapy.
onclusions. A clinically significant reduction in AF is seen
n patients treated with either ACEIs or ARBs. There is
ubstantial heterogeneity between the trials included in this
nalysis, which is partially explained by differences in patient
opulation and LV function. The reduction in AF with
CEIs and ARBs appears to be related, in part, to the
emodynamic effects of these drugs, although these two classes
f agents may also possess specific properties that help prevent
F. Ongoing research will help clarify these issues.
eprint requests and correspondence: Dr. Jeff S. Healey, Mc-
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